The burden of skin diseases: 2004

Bickers, David R.; Lim, Henry W.; Margolis, David J.; Weinstock, Martin A.; Goodman, Clifford; Faulkner, E. J.; Gould, C. Linn; Gemmen, Eric; Dall, Timothy M.

doi:10.1016/j.jaad.2006.05.048

Cited by 641 publications

(235 citation statements)

References 10 publications

Supporting

Mentioning

227

Contrasting

Unclassified

Order By: Relevance

“…Over 5.4 million of these cancers are diagnosed in 3.3 million people in the United States annually, 2,3 and the global burden of disease from keratinocyte carcinomas is estimated at 12.9 disability-adjusted life years per 100,000 persons. 4 Generally keratinocyte carcinomas are not aggressive and do not metastasize or kill as often as melanoma, which is the third most common skin cancer.…”

Section: Introduction Backgroundmentioning

confidence: 99%

“…7 A more common problem is that basal and squamous cell carcinomas and their treatment may result in disfigurement or disability, which can adversely impact quality of life. 3 The recent Surgeon General's call to action to prevent skin cancer at the population level emphasizes the public health importance of dealing with keratinocyte carcinomas. 8 Because of their frequency, BCC and SCC are the fifth most expensive cancer at the population level, and, being more common in older adults, their management is of great importance to Medicare.…”

Section: Introduction Backgroundmentioning

confidence: 99%

“…8 Because of their frequency, BCC and SCC are the fifth most expensive cancer at the population level, and, being more common in older adults, their management is of great importance to Medicare. 2,3,9 It is estimated that in 2012 over 2 million Medicare beneficiaries underwent intervention for BCC or SCC. 2 There are many potential management strategies for keratinocyte carcinoma, and they can be broadly grouped into eight main categories: (1) surgical excision without intraoperative evaluation of the margins, (2) surgical excision with intraoperative evaluation of the margins, (3) destruction via temperature gradients, (4) ionizing radiation, (5) photodynamic interventions, (6) medical therapies, along with (7) combinations of these therapies, and (8) watchful waiting.…”

Section: Introduction Backgroundmentioning

confidence: 99%

“…3,9,34,35 Payers are faced with increased utilization of costly therapies, such as brachytherapy, without clear evidence for relative benefits to justify increased costs.…”

Section: Introduction Backgroundmentioning

confidence: 99%

“…In addition, interventions for treating skin cancers differ substantially in cost. 3,[8][9][10] The objective of this systematic review is to comprehensively synthesize information on the comparative effectiveness and safety of each of the above-mentioned therapeutic strategies for both BCC and SCC. …”

mentioning

confidence: 99%

See 4 more Smart Citations

Treatments for Basal Cell and Squamous Cell Carcinoma of the Skin

Drucker¹,

Adam²,

Langberg³

et al. 2017

Self Cite

View full text Add to dashboard Cite

Key MessagesPurpose of Review Assess comparative effectiveness and safety of treatments for basal cell carcinoma (BCC) and squamous cell carcinoma (SCC). Key Messages• Comparative evidence on treatment of BCC and SCC is limited. Many comparisons were evaluated in one or two randomized controlled trials only.• Surgery and radiotherapy have lower recurrence rates for BCC than interventions that destroy lesions with heat or cold, photodynamic therapy (PDT), or curettage.• There is moderate confidence that PDT for BCC is associated with better cosmetic outcomes than surgery.• Serious adverse events, events leading to treatment discontinuation, and treatment site infections were uncommon with all treatments for BCC.• Recurrence rates for SCC in situ were lower with PDT and cryotherapy than with drugs.Evidence was insufficient to draw conclusions for other treatments.ii This report is based on research conducted by the Brown Evidence-based Practice Center (EPC) under contract to the Agency for Healthcare Research and Quality (AHRQ), Rockville, MD (Contract No. 290-2015-00002-I). The findings and conclusions in this document are those of the authors, who are responsible for its contents; the findings and conclusions do not necessarily represent the views of AHRQ. Therefore, no statement in this report should be construed as an official position of AHRQ or of the U.S. Department of Health and Human Services.None of the investigators have any affiliations or financial involvement that conflicts with the material presented in this report.The information in this report is intended to help health care decisionmakers-patients and clinicians, health system leaders, and policymakers, among others-make well-informed decisions and thereby improve the quality of health care services. This report is not intended to be a substitute for the application of clinical judgment. Anyone who makes decisions concerning the provision of clinical care should consider this report in the same way as any medical reference and in conjunction with all other pertinent information, i.e., in the context of available resources and circumstances presented by individual patients.This report is made available to the public under the terms of a licensing agreement between the author and the Agency for Healthcare Research and Quality. This report may be used and reprinted without permission except those copyrighted materials that are clearly noted in the report. Further reproduction of those copyrighted materials is prohibited without the express permission of copyright holders.AHRQ or U.S. Department of Health and Human Services endorsement of any derivative products that may be developed from this report, such as clinical practice guidelines, other quality enhancement tools, or reimbursement or coverage policies, may not be stated or implied. This report may periodically be assessed for the currency of conclusions. If an assessment is done, the resulting surveillance report describing the methodology and findings will be found on the Effective Health Ca...

show abstract

Section: Introduction Backgroundmentioning

confidence: 99%

Section: Introduction Backgroundmentioning

confidence: 99%

Section: Introduction Backgroundmentioning

confidence: 99%

“…3,9,34,35 Payers are faced with increased utilization of costly therapies, such as brachytherapy, without clear evidence for relative benefits to justify increased costs.…”

Section: Introduction Backgroundmentioning

confidence: 99%

mentioning

confidence: 99%

See 3 more Smart Citations

Treatments for Basal Cell and Squamous Cell Carcinoma of the Skin

Drucker¹,

Adam²,

Langberg³

et al. 2017

Self Cite

View full text Add to dashboard Cite

show abstract

Annual Direct and Indirect Health Care Costs of Chronic Idiopathic Urticaria

DeLong

Culler

Saini³

et al. 2008

Arch Dermatol

129

View full text Add to dashboard Cite

To estimate annual direct and indirect health care costs in patients with chronic idiopathic urticaria (CIU) managed with conventional therapies.Design: A cost analysis consisting of a survey-guided and retrospective medical record review of direct and indirect health care costs from a societal perspective in patients with CIU.Setting: The Johns Hopkins University allergy and dermatology ambulatory clinics.Participants: Fifty adults with active CIU were recruited in sequential order. Individuals who were taking corticosteroids or other immunosuppressants in the month before enrollment were excluded from the study. Main Outcome Measures:We estimated direct health care costs, which included laboratory, medication, outpatient visit, and emergency department and hospital visit costs. We also estimated indirect costs, which included earnings lost owing to travel to outpatient visits and absences from work owing to CIU-related illness.

show abstract